Bionano Genomics Holds 2024 Annual Meeting

TL;DR

BNGO stockholders met, voted on directors & pay. Results are in.

AI Summary

Bionano Genomics, Inc. announced on June 18, 2024, that it held its 2024 Annual Meeting of Stockholders. During the meeting, stockholders voted on several proposals, including the election of directors and an advisory vote on executive compensation. The company also reported on the outcome of these votes.

Why It Matters

The outcomes of the stockholder votes at the annual meeting can impact the company's governance and executive compensation structure, potentially influencing future strategic decisions and investor confidence.

Risk Assessment

Risk Level: low — This filing is a routine update on a shareholder meeting and does not contain significant new financial or operational information that would immediately alter the company's risk profile.

Key Players & Entities

• Bionano Genomics, Inc. (company) — Registrant
• 2024 Annual Meeting of Stockholders (event) — Subject of the filing
• June 18, 2024 (date) — Date of the event

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Sto

Filing Documents

• bngo-20240618.htm (8-K) — 35KB
• 0001411690-24-000040.txt ( ) — 155KB
• bngo-20240618.xsd (EX-101.SCH) — 2KB
• bngo-20240618_lab.xml (EX-101.LAB) — 21KB
• bngo-20240618_pre.xml (EX-101.PRE) — 12KB
• bngo-20240618_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 18, 2024, Bionano Genomics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 22, 2024, the record date for the Annual Meeting (the "Record Date"), 66,856,804 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. A total of 30,047,684 shares of the Company's common stock were present at the Annual Meeting in person, by virtual attendance, or by proxy, which represents approximately 44.94% of the shares of the Company's common stock outstanding as of the Record Date. Proposal 1. Election of Directors. The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows: Name Votes For Votes Withheld Broker Non-Votes Christopher Twomey 10,442,715 1,480,283 18,124,686 Yvonne Linney, Ph.D. 10,682,829 1,240,169 18,124,686 Aleksander Rajkovic, M.D., Ph.D. 10,810,303 1,112,695 18,124,686 Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers. The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,508,999 1,771,611 642,388 18,124,686 Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered public accounting f

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bionano Genomics, Inc. Date: June 21, 2024 By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR